Journal Information
Vol. 19. Issue 4.
Pages 188-196 (April 2023)
Share
Share
Download PDF
More article options
Visits
1588
Vol. 19. Issue 4.
Pages 188-196 (April 2023)
Original article
Full text access
Utility of neutrophil/albumin ratio and C-reactive protein/albumin ratio as novel inflammatory markers in Behcet's disease
Utilidad de la relación neutrófilos/albúmina y la relación proteína C reactiva/albúmina como nuevos marcadores inflamatorios en la enfermedad de Behçet
Visits
1588
Doaa E. Kamala, Rabab S. Zaghlola,b,
Corresponding author
rababzaghlol@yahoo.com

Corresponding author.
, Marwa H.S. Hussienc, Wafaa K. Makarma
a Rheumatology and Rehabilitation Department, Faculty of Medicine, Zagazig University, Egypt
b Physical Medicine and Rehabilitation Department, Security Forces Hospital, Makkah, Saudi Arabia
c Medical Biochemistry Department, Faculty of Medicine, Zagazig University, Egypt
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Abstract
Introduction and objectives

Behcet's disease (BD) is an autoimmune systemic inflammatory disease, and its exact pathogenesis is unknown. There are currently no specific tests to evaluate the disease activity of BD, making its management more difficult. This study aims to determine the neutrophil/albumin ratio (NAR) and C-reactive protein (CRP) to albumin ratio (CAR) and investigate their associations with clinical findings in patients with BD and to determine optimum cutoff levels of CAR and NAR.

Methods

The study included 75 consecutively recruited patients with BD with a mean age of 33.29±6.23 years and disease duration of 7.21±4.64 years, as well as 75 healthy participants. Clinical characteristics and laboratory data were obtained. Disease activity was assessed using the BD current activity form score (BDCAF).

Results

NAR and CAR were elevated in patients with BD compared with those of healthy controls (NAR: 1.08±0.34 vs. 0.607±0.06, CAR: 2.49±1.73 vs. 0.39±0.142; p<0.0001), as well as in active BD versus inactive BD. Both NAR and CAR were significantly correlated with CRP, active uveitis, and BDCAF score (p0.05). In patients with active BD, the cutoff value of NAR was >0.9744 (sensitivity: 89.74%, specificity: 80.56%), while that of CAR was >2.04 (sensitivity: 74.36%, specificity: 83.33%).

Conclusions

NAR and CAR are both elevated in patients with BD and may contribute to its active state. NAR and CAR can be feasible and inexpensive markers for predicting BD activity.

Keywords:
Behcet
C-reactive protein to albumin ratio
Neutrophil to albumin ratio
Resumen
Introducción y objetivos

La enfermedad de Behçet (EB) es una enfermedad inflamatoria sistémica autoinmune y se desconoce su patogenia exacta. Actualmente no existen pruebas específicas para evaluar la actividad de la EB, lo que dificulta su manejo. El objetivo de este estudio es determinar la proporción neutrófilos/albúmina (NAR) y de proteína C reactiva (CRP)/albúmina (CAR) e investigar sus asociaciones con los hallazgos clínicos en pacientes con EB y determinar los niveles de corte óptimos de CAR y NAR.

Métodos

El estudio incluyó a 75 pacientes con EB reclutados consecutivamente con una edad media de 33,29±6,23 años y una duración de la enfermedad de 7,21±4,64 años, así como a 75 participantes sanos. Se obtuvieron características clínicas y datos de laboratorio. La actividad de la enfermedad se evaluó utilizando la puntuación del formulario de actividad actual de la EB (BD Current Activity Form [BDCAF]).

Resultados

NAR y CAR estaban elevados en pacientes con EB en comparación con controles sanos (NAR: 1,08±0,34 vs. 0,607±0,06, CAR: 2,49±1,73 vs. 0,39±0,142; p<0,0001), así como en pacientes EB activos versus EB inactivos. Tanto la NAR como la CAR se correlacionaron significativamente con la PCR, la uveítis activa y la puntuación BDCAF (p0,05). En pacientes con EB activa, el valor de corte de NAR fue>0,9744 (sensibilidad: 89,74%, especificidad: 80,56%), mientras que el de CAR fue>2,04 (sensibilidad: 74,36%, especificidad: 83,33%).

Conclusiones

NAR y CAR están elevados en pacientes con EB y pueden contribuir a su estado activo. NAR y CAR pueden ser marcadores factibles y económicos para predecir la actividad de EB.

Palabras clave:
Behçet
Proporción proteína C reactiva/albúmina
Relación neutrófilos/albúmina
Full Text
Introduction

Behcet's disease (BD) is a chronic multisystemic disease of unknown etiology. It can affect a variety of organs and can go into remission and relapse. Characteristic BD features include recurrent oral, genital, and mucosal ulceration, uveitis, and cutaneous lesions. The neurological, cardiovascular, gastrointestinal, and musculoskeletal systems may also be involved.1–3 Neutrophil hyperfunction, vasculitis, and autoimmune reactions appear to be responsible for the disease.4,5

Several laboratory tests have been studied for their ability to reflect disease activity, evaluate treatment efficacy, or predict future complications of BD, but no particular test has been found to detect disease activity.6–9 Nevertheless, the C-reactive protein (CRP) to albumin ratio (CAR) has been proposed as a better indicator of inflammatory response compared with CRP or albumin alone.10,11 CAR is a well-established predictor of a variety of diseases, including rheumatoid arthritis, BD uveitis, heart disease, and various cancers.12–14 Furthermore, higher levels of CAR are also associated with poor prognosis and worse treatment outcomes in systemic diseases.15,16

The neutrophil/albumin ratio (NAR) has been reported as a new inflammatory indicator in severe infection, cancer, and schizophrenia. In patients with cancer, a higher level of NAR was found to represent an increased inflammatory state, which poorly affects prognosis and treatment response.17 Neutrophils, the key components of the innate immune system, are activated and recruited to the target tissue by inflammatory mediators due to the chronic inflammatory status of BD, causing damage and organ dysfunction.18 Hypoalbuminemia in BD reflects the underlying active inflammatory state; the decrease in hepatic albumin production (a negative acute-phase reactant) may be caused by increased inflammatory mediators.19 However, NAR has not been studied in BD.

Thus, we aim to examine the value of the CAR and NAR in patients with BD in terms of their associations with clinical characteristics, as well as to determine their optimum cut-off levels. In this study, we hypothesized that CAR and NAR are associated with disease activity and can serve as novel inflammatory markers in BD.

MethodsStudy design

This case-control study was conducted in the Rheumatology & Rehabilitation Departments, Faculty of Medicine, Zagazig University.

Study population

The study included 75 patients with BD who were routinely followed up at the Department of Rheumatology, Rehabilitation, and Physical Medicine, Faculty of Medicine, Zagazig University, from January 2021 to May 2021. BD diagnosis was made according to the revised International Criteria for Behcet's Disease 2010 criteria.20 The study also included a control group of 75 healthy adults of the same age and gender. We excluded patients with other autoimmune diseases or systemic disorders (i.e., malignancy, diabetes mellitus, heart failure, hepatic dysfunction, renal dysfunction, acute infection, and chronic infection). Informed consent was obtained from each subject before their participation in the study. Approval was obtained from the ethics committee of the university (registration number: ZU-IRB 6614/19-9-2019). The study was conducted in accordance with the ethical standards of the Declaration of Helsinki.

Data collection

Patient data were gathered from their medical records, including demographic data, such as name, age, sex, and disease duration. Furthermore, the same rheumatologist carried out a comprehensive history and clinical examination in all patients.

Determination of disease activity

Disease activity during the past 4 weeks was evaluated using the validated Turkish version of the BD Current Activity Form (BDCAF). The presence of active disease was defined as having a BDCAF score of ≥2 out of 12.21

Laboratory investigations

A complete blood count including the differential count, erythrocytes sedimentation rate (ESR), CRP, and serum albumin were obtained from patients with BD and healthy controls. The white blood cell (WBC), neutrophil, lymphocyte, and platelet counts were recorded. The neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), NAR, and CAR were calculated from these parameters.

In our hospital, complete blood counts were determined using the Sysmex KX-21 hematology analyzer (Sysmex Corporation, America), and albumin was measured using the automated clinical chemistry analyzer Cobas Integra 400 plus (Roche Diagnostics, Deutschland). CRP levels were measured using automated nephelometry BN Prospec (Siemens, UK), and ESR was analyzed in the 1st hour using Westergren's method.

Statistical analysis

All data were collected, tabulated, and statistically analyzed using SPSS 20.0 for Windows (SPSS Inc., Chicago, IL, USA 2011). Quantitative data were expressed as the mean±standard deviation and median (range), and qualitative data were expressed as absolute frequencies (number) and relative frequencies (percentage). Comparisons of normally distributed continuous variables were carried out using independent samples Student's t-test, while the Mann–Whitney U test was used for non-normally distributed data. Percent of categorical variables were compared using Chi-square test or Fisher's exact test when appropriate. Relationships of the NAR and CAR ratio with various parameters of BD were assessed by calculating Pearson's and Spearman's correlation coefficients. To differentiate between patients with active and inactive BD, the optimal cut-off values of the NAR, CAR, CRP, ESR, NLR, and PLR with the maximum sensitivity and specificity were calculated via receiver operating characteristic (ROC) curve analysis. The -statistic was used to compare the areas under the ROC curves (AUCs). p-Values of ≤0.05 were statistically significant, whereas p-values of >0.05 were considered statistically insignificant.

Results

The main clinical characteristics of the 75 patients with BD are summarized in Table 1. Oral ulceration (77.3%) and genital ulceration (69.3%) were the most common clinical features of patients with BD, whereas pulmonary and arterial involvement was the least common (1.33%). The mean duration of BD was 7.21±4.64 years. The median disease activity score assessed via BDCAF was 2 (range: 1–4). Accordingly, 39 patients were considered to have active BD.

Table 1.

Clinical characteristics of patients with BD.

Variables  Behcet patients (n=75) 
Disease duration (year)  7.21±4.64, 7 (1–24) 
Oral ulcer  58 (77.3%) 
Genital ulcers  52 (69.3%) 
Papulopustular lesions  3 (4%) 
Erythema nodosum  2 (2.6%) 
Pathergy test  4 (5.3%) 
Articular manifestations  22 (29.3%) 
Ocular affection  38 (50.6%) 
Active Uveitis  29 (38.6%) 
Anterior uveitis  4 (5.3%) 
Posterior uveitis  34 (45.3%) 
Pan uveitis  3 (4%) 
Arterial involvement  1 (1.33%) 
Venous involvement  34 (45.3%) 
Deep venous thrombosis  6 (8%) 
Superficial thrombophlebitis  7 (9.33%) 
Neurological involvement  5 (6.6%) 
Pulmonary involvement  1 (1.33%) 
Cardiovascular involvement  11 (14.7%) 
BDCAF score, median (range)  1.94±1.005, 2 (1–4) 
Active disease, n (%)  39 (52%) 
Treatment
Colchicine  28 (37.3%) 
Dapsone  3 (4%) 
Corticosteroids  53 (70.6%) 
Azathioprine  35 (46.7%) 
Cyclophosphamide  6 (8%) 
Cyclosporine  4 (5.3%) 
Chlorambucil  1 (1.33%) 
Methotrexate  5 (6.7%) 
Infliximab  17 (22.6%) 
Adalimumab  22 (29.3%) 
Anticoagulants  6 (8%) 

Values are stated as number and percentage n (%), mean±Sd or median (range), BDCAF: Bechet's disease current activity form.

Our study included 75 patients with BD with a mean age of 34.29±6.23 years (24 females, 51 males) and 75 healthy controls matched for age and sex (p>0.05). Patients with BD had significantly increased levels of ESR, CRP, albumin, WBCs, neutrophil, NLR, and PLR compared with those of controls (p0.05). Furthermore, patients with BD also had significantly increased NAR (1.08±0.34; p<0.0001) and CAR (2.49±1.73; p<0.0001) compared with those of controls. However, the two groups did not differ significantly in the other parameters, such as body mass index, hemoglobin level, and platelet and lymphocyte counts (p>0.05) (Table 2).

Table 2.

Demographic and laboratory results of Behcet patients and controls.

Variables  Behcet patients (n= 75)  Control (n =75)  p value 
Age (years)  33.29±6.23  32.96 ± 5.33  0.16a 
  34 (22-57)  33 (24-54)   
Gender       
Female  24 (32%)  27 (36%)  0.61c 
Male  51 (68%)  48 (64%)   
BMI (kg/m224.47 ± 2.43  24.62 ± 2.05  0.68a 
  24.2 (21.4-31.8)  24.5 (21.4-32.2)   
ESR, mm/h  28 (3-130)  18 (10-28)  0.001b
CRP, mg/ dL  10.3 ± 7.2  1.71 ± 0.63   
  10 (0.12 - 33.6)  1.6 (0.3 -3.5)  0.0001a
Albumin (g/dl)  4.22 ± 0.34  4.46 ± 0.19   
  4.2 (3.49-4.81)  4.39 (3.64-4.8)  0.001a
HGB  12.84 ± 0.65  12.88 ± 0.65  0.68a 
  12.7 (11.9-15)  12.9 (12.3-14.7)   
WBCS, (x103/mm38.16 ± 1.704  5.89 ± 1.17  < 0.0001a
  7.9 (4.2-15.4)  5.6 (4.2-8.8)   
Platelets, (x103/mm3272 (201 -402)  265 (228-320)  0.13b 
Neutrophil, × (x103/mm34.551 ± 1.36  2.725 ± 0.30  < 0.0001a
  4.4 (2.5-7.6)  2.7 (2.2-3.4)   
Lymphocyte, × (x103/mm32.23 ± 0.531  2.15 ± 0.34  0.289a 
  2.2 (1.4-3.2)  2.1 (1.3-2.9)   
NLR  2.109 ± 0.67  1.31 ± 0.28  0.0001a
  2.04 (0.8-5.2)  1.27 (0.16-2)   
PLR  122.17 (52.64-202.66)  116.1 (79.31-168.8)  0.0397b
CAR  2.49 ± 1.73  0.39 ± 0.142   
  2.4 (0.02-7.3)  0.37 (0.074-0.755)  0.0001a
NAR  1.08 ± 0.34  0.607 ± 0.06   
  1.1 (0.31-3.2)  0.6 (0.33-0.48)  0.0001a

All values are presented a number and percentage n (%), mean±Sd or median (range), number (%) or mean±SD.

a

Independent t-test.

b

Mann–Whitney U test.

c

Chi-square test.

HG: hemoglobin, WBC: white blood cells, CAR: C-reactive protein/albumin ratio, NAR: neutrophil/albumin ratio, PLR: platelet/lymphocyte ratio, NLR: neutrophil/lymphocyte ratio, p0.05=significant.

When we compared patients in the active (n=39) and inactive BD (n=36) state, significant differences were found in the ESR, CRP, WBC count, neutrophil count, serum albumin, and NLR (p=0.004, p<0.001, p=0.0039, p=0.001, p=0.002, and p=0.0008, respectively). Patients with active BD (n=39) had a significantly higher NAR compared with those with inactive BD (n=6, p<0.0001). Furthermore, patients with active BD had a significantly increased CAR compared with those with inactive BD (p<0.0001) (Table 3).

Table 3.

Comparison of parameters according to disease activity in BD.

Variables  Active  Inactive  T test  P value 
  n=39  n=36     
Age  34.82±8.85  34.44±5.72     
  35 (22-57)  34.5 (26-48)  t = 0.21  0.82a 
Gender (female/male)  11/28  13/23  0.537  0.46c 
Disease duration  6.46±4.24  8.36±4.72     
  6 (1-14)  8 (2-24)  t = 1.836  0.0704a 
ESR (mm/hour)  31 (5-130)  20 (3-65)  u=3.48  .004b
CRP (mg/L)  14.19±6.97  6.231±4.92     
  14.2 (0.2-33.6)  6.1 (0.12-26.8)  t = 5.66  < .0001a
WBCS, (x103/mm38.68±1.95  7.58±1.088     
  8.5 (5-15.4)  7.5 (4.2-10)  t = 2.9822  0.003a
Neutrophil, × (x103/mm35.21±1.45  3.83±0.7     
  5.1 (3-7.6)  3.7 (2.5-5.8)  t = 5.149  0. 001a
HGB  12.856±0.609  12.85±0.682     
  12.7 (11.9-14.6)  12.7 (12-15)  t = 0.04  0.96a 
Lymphocyte, × (x103/mm32.31±0.61  2.13±0.387     
  2.3 (1.5-3.2)  2.1 (1.4-2.8)  t = 1.511  .135a 
Platelets, (x103/mm3268 (201-402)  248.5 (201-316)  u=1.67  0.094b 
Albumin (g/dl)  4.16±0.28  4.38±0.31     
  4.1 (3.49-4.6)  4.2 (3.7.4.81)  t=3.18  0.002a
NLR  2.349±0.734  1.847±0.475     
  2.2 (1.6-5.2)  1.7 (0.8-2.9)  t = 3.484  0.0008a 
PLR  123.63 (52.641-202.66)  116.84 (80-158.64)  u= 1.33  0.18b 
CAR  3.26±1.56  1.4659±1.182     
  3.2 (0.04-7.3)  1.3 (0.02-6.3)  t = 5.6  <0.00001a
NAR  1.236±0.3149  0.882±0.2028     
  1.2 (0.65-3.2)  0.86 (0.31-1.26)  t = 5.73  <0.0001a

All values are presented a number and percentage n (%), mean±Sd or median (range), number (%) or mean±SD.

a

Independent t-test.

b

Mann–Whitney U test.

c

Chi-square test.

WBC: white blood cells, CAR: C-reactive protein/albumin ratio, NAR: neutrophil/albumin ratio, PLR: platelet/lymphocyte ratio, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, NLR: neutrophil/lymphocyte ratio.

Gender and smoking habits were not significantly associated with either NAR or CAR among patients with BD (p>0.05). However, NAR levels tended to be higher in patients with BD with oral ulceration, articular involvement, and ocular involvement (i.e., active uveitis) (p=0.0416, p=0.0493, and p=0.0108, respectively) compared with those without involvement. Similarly, a significant difference regarding CAR was found in patients with BD with ocular involvement (active uveitis) (p=0.0349) compared with those without active uveitis. Thus, NAR was closely linked to the presence of oral ulcerations and articular manifestations, whereas CAR was not. Otherwise, neither NAR nor CAR levels were affected by the presence of vascular, pulmonary, cardiovascular, or neurological involvements in BD (p>0.05) (Table 4).

Table 4.

Comparison of CAR and NAR according to BD characteristics.

Variables  CAR, mean±SD  p value  NAR, mean±SD  p value 
Gender
Female (24)  2.628±1.85  p=0.60  0.998±0.248  p=0.16 
Male (51)  2.401±1.758    1.117±0.376   
Smoking
Yes (22)  2.156±1.56  p=0.2922  1.076±0.3752  p=0.93 
No (53)  2.623±1.87    1.083±0.2703   
Oral ulcer
Present (58)  2.628±1.79  p=0.17  1.120±0.351  p=0.0416* 
Absent (17)  1.947±1.67    0.936±0.182   
Genital ulcers
Present (52)  2.298±1.78  p=0.204  2.156±1.5625  p=0.26 
Absent (23)  2.871±1.75    2.623±1.8716   
Rash
Present (5)  1.858±1.59  p=0.21  1.085±0.3127  p=0.94 
Absent (70)  2.580±1.80    1.077±0.3506   
Articular manifestations
Present (22)  2.854±1.84  p=0.28  1.209±0.5081  p=0.049* 
Absent (53)  2.345±1.759    1.034±0.2573   
Active uveitis
Present (29)  2.905±1.617  p=0.0349*  1.183±0.239  p=0.0108* 
Absent (46)  2.007±1.855    0.966±0.402   
Venous involvement
Present (28)  2.723±1.694  p=0.31  1.087±0.281  p=0.85 
Absent (47)  2.298±1.84    1.072±0.384   
Superficial thrombophlebitis
Present (7)  2.397±1.6626  p=0.841  0.967±0.222  p=0.123 
Absent (68)  2.496±1.8282    1.111±0.366   
Cardiovascular involvement
Present (11)  2.489±1.776  p=0.976  1.115±0.396  p=0.69 
Absent (64)  2.471±1.796    1.072±0.337   
NeuroBechet
Present (5)  2.068±1.634  p=0.441  1.012±0.324  p=0.504 
Absent (70)  2.536±1.806    1.089±0.347   

All values are stated as mean and SD, CAR: C-reactive protein/albumin ratio, NAR: neutrophil/albumin ratio, NLR: neutrophil/lymphocyte ratio.

*

Significant0.05.

The ROC curve analyses for CAR and NAR as well as other inflammatory markers were performed to evaluate the disease activity in patients with BD included in the study. Specifically, CAR was compared with the CRP and albumin levels as presented in Table 5. The AUC of the NAR (0.849, 95% confidence interval [CI]: 0.747–0.921, p<0.0001) and CAR (0.777, 95% CI: 0.666–0.865, p<0.001) in patients with BD were higher than those of albumin, neutrophil count, CRP, and ESR. Fig. 1 depicts the discriminatory value of these indicators in relation to the BDCAF score.

Table 5.

ROC curve analysis of NAR and CAR and other inflammatory markers to differentiate between active and inactive Behcet disease.

Variable  Cut-off value  Sensitivity  Specificity  AUCs  95% CI  p value 
Neutrophils  >4.5  74.36  77.78  0.762  0.650–0.853  <0.001* 
Albumin  ≤4.16  64.10  86.11  0.733  0.618–0.829  <0.002* 
CAR  >2.0444  74.36  83.33  0.777  0.666–0.865  <0.001* 
NAR  >0.9744  89.74  80.56  0.849  0.747–0.921  <0.0001* 
CRP (mg/dl)  >9.3  71.79  86.11  0.759  0.647–0.851  <0.001* 
ESR (mm/hr.)  >29  61.54  72.22  0.679  0.562–0.783  0.0045* 

CAR: C-reactive protein/albumin ratio, NAR: neutrophil/albumin Ratio, CR: C-reactive protein, ESR: erythrocyte sedimentation rate.

*

Significant0.05.

Fig. 1.

(a) ROC curve of NAR in predicting active BD. (b) ROC curve of CAR in predicting active BD. (c) ROC curve of NAR and CAR versus other inflammatory markers in predicting active BD.

(0.33MB).

In patients with BD, NAR had significant positive correlations with the presence of active uveitis (r=0.31, p<0.006), oral ulcerations (r=0.244, p=0.034), joint involvement (0.236, p=0.041), BDCAF score (r=0.59, p<0.001), ESR (r=0.153, p=0.028), CRP (r=0.230, p=0.04), neutrophil count (r=0.69, p<0.001), NLR (r=0.67, p<0.0001), and CAR (r=0.28, p=0.014). Moreover, CAR also had significant positive correlations with the presence of active uveitis (r=0.25, p=0.03), BDCAF score (r=0.541, p<0.001), CRP (r=0.49, p<0.0001), and NAR (r=0.28, p=0.014). Furthermore, both CAR (r=−0.369, p=0.011) and NAR (r=−0.451, p=0.0004) had significant negative correlations with serum albumin. Other parameters such as age, disease duration, mucocutaneus involvement, vascular involvement, and PLR were not correlated with either NAR or CAR (p>0.05) (Table 6, Fig. 2).

Table 6.

Correlations of CAR and NAR with patients’ characteristics in BD.

Variable  CAR(n=75)NAR(n=75)
  r  p value  r  p value 
Age  0.19  0.102  0.18  0.12 
Disease duration  0.22  0.0578  0.11  0.34 
Mucocutaneous manifestations  0.161  0.173  0.201  0.083 
Oral ulceration  0.049  0.67  0.244  0.034* 
Articular manifestations  0.109  0.35  0.236  0.041* 
Active uveitis  0.25  0.03*  0.31  0.006* 
Vascular involvement  0.11  0.34  0.03  0.79 
BDCAF score  0.541  <0.001*  0.59  <0.001* 
CRP (mg/dl)  0.49  <0.0001*  0.230  0.04* 
ESR (mm/h)  0.22  0.057  0.153  0.028* 
Albumin (g/dl)  −0.369  .0011*  −0.451  .0004* 
WBCS, (×103/mm30.096  0.442  0.192  .098 
Neutrophil, (×103/mm30.19  0.102  0.69  <0.001* 
Lymphocyte, (×103/mm30.21  .0705  0.133  0.255 
Platelets, (×103/mm30.10  0.36  0.145  0.214 
NLR  0.020  0.86  0.67  <0.0001* 
PLR  0.12  0.305  0.004  0.970 
NAR  0.28  0.014*  –  – 
CAR  –  –  0.28  0.014* 

BDCAF: Bechet's disease current activity form; ESR: erythrocyte sedimentation rate; CR: C-reactive protein; CAR: C-reactive protein/albumin ratio, NAR: neutrophil/albumin ratio, PLR: platelet to lymphocyte ratio, NLR: neutrophil/lymphocyte ratio.

*

p significant ≤0.05.

Fig. 2.

(a) The correlation between NAR and BDCAF in patients with BD. (b) Correlation between CAR and BDCAF in patients with BD. (c) Correlation of NAR and CRP in patients with BD (d) Correlation of NAR and CAR in patients with BD.

(0.21MB).
Discussion

The principal finding of the present study was that patients with BD had higher NAR and CAR values than healthy controls especially during the active stage of the disease, even in those of treated patients with BD. Moreover, comparisons showed that these two parameters were positively correlated with CRP, active uveitis, and BDCAF score. Previous studies have shown that CAR levels correlated with the activity of different autoimmune and rheumatic diseases.22 However, no studies have associated CAR and NAR with the different clinical manifestations and disease activity in patients with BD.

Although acute-phase protein, immunoglobulin, complement, autoantibody, lymphocyte, surface indicator, and cytokine levels are used as indicators of BD activity, there is no specific indicator for disease activation.6 Previously, the total BDCAF score was found to correlate well with both ESR and CRP levels, but there are still conflicting findings regarding the relationship between these parameters and clinical disease activity in BD.23 Recently, studies have suggested that CAR and NAR are reliable biomarkers of inflammation, and a combination of inflammatory markers including CAR and NAR can be used to indicate increased inflammatory status.24 Besides CAR and NAR, we also evaluated ESR, CRP, NLR, and PLR, all of which have been investigated in several studies.

Similarly, in a study comparing the inflammatory markers between patients with acutely exacerbated and remitted schizophrenia and healthy controls,24 CAR and NAR levels were found to be significantly higher in patients with schizophrenia than in control subjects. The authors proposed that a combination of inflammatory markers including CAR and NAR could be used to reflect the increased inflammatory status in schizophrenia. In accordance with this, a retrospective study of 32 patients with and 32 healthy controls found that CAR had the highest correlation with disease activity in patients with Takayasu arteritis.22

In our study, serum NAR was significantly increased in patients with active BD (n=39) compared with those with inactive BD (n=36, p<0.0001). Furthermore, patients with active BD had a significantly increased CAR compared with those with inactive BD (p<0.0001). Both CAR and NAR also had significant positive correlations with the BDCAF score.

Interestingly, NAR was significantly correlated with NLR (p0.05), whereas PLR was not correlated with either NAR or CAR (p>0.05). Significant differences in NLR values were also found in patients with active BD versus those with inactive BD; this is consistent with a previous Egyptian study, which concluded that NLR was higher in patients with active BD than in those with inactive BD (p<0.01). Although both NLR and PLR were correlated with BDCAF, the correlation of NLR with BDCAF was significantly stronger than that of PLR.25

Moreover, a recent study revealed that active BD was associated with higher NLR and PLR, but only a slight correlation between NLR and BD activity. Those authors recommended further separate investigations of PLR and NLR and their relationship with various manifestations of the disease, since NLR and PLR seem to have specific associations with BD activity.26

Similarly, two studies have found CAR to be a useful biomarker in describing the activity of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.26,27 This finding is consistent with other studies investigating the correlation of CAR and NAR with other inflammatory mediators in various diseases.24 On the other hand, in a cross-sectional study of 121 patients with rheumatoid arthritis assessing the relationship of CAR with disease activity, quality of life, and physical function, a significant but weak correlation between CAR and disease activity was found among the enrolled patients.11

Patients with BD with oral ulcerations had significantly higher articular involvement, ocular involvement (active uveitis), and NAR than in those without involvement. Similarly, patients with BD with active uveitis had a considerable difference in CAR value compared with those without active uveitis. Thus, NAR was closely associated with the presence of oral ulcerations and articular manifestations, whereas CAR was not. However, no studies have been conducted to compare CAR and NAR based on BD characteristics.

In our study, ROC interpretation revealed that the NAR and CAR values in patients with active BD had an AUC of 0.849 and 0.777, respectively, which are higher than those of albumin, neutrophil count, CRP, and ESR. The cut-off value of NAR in our study was >0.9744, and this had a sensitivity of 89.74% (the highest sensitivity percentage among patients with active BD) and a specificity of 80.56%. On the other hand, CAR had a cut-off value of >2.0444, with a sensitivity and specificity of 74.36% and 83.33%, respectively. To date, no studies have previously provided cut-off values or AUC for BD activity.

However, it was previously reported that the AUC of CAR was 0.801 when used to predict the existence of uveitis among patients with BD; this was remarkably high compared with the AUCs of other inflammatory biomarkers.28 In line with this, another study in patients with systemic sclerosis identified the AUC of CAR to be 0.788 (p=0.000), which was significant with a 95% CI of 0.651–0.925.29

Notably, CAR is accepted as an important parameter in the prognosis and follow-up of many diseases. It is used as a prognostic marker for disease activity and mortality, especially in inflammatory conditions, such as sepsis and septic shock.15 The novelty of this study lies in the comparison of CAR and NAR in patients with BD with different clinical and laboratory findings as well as disease activity.

BD is characterized by chronic relapsing episodes and may cause significant morbidity and mortality due to ocular, vascular, and neurological involvements. Early prediction of disease activity may enable clinicians to aggressively manage the disease to prevent the occurrence of complications.30 However, further research is still required to establish the optimal laboratory tests for predicting BD activity.

Limitations

Our study had some limitations. First, this study was a single-center case–control study. Furthermore, the duration of the treatment in each patient could have changed CAR and NAR levels; this should be investigated in future studies to confirm their diagnostic potential. Nevertheless, large multicenter prospective studies are needed to verify our findings.

Conclusions

NAR and CAR are elevated in patients with BD and may contribute to the active disease state. Our results suggested that NAR and CAR are feasible and inexpensive tools for predicting BD activity.

Key points

  • CAR and NAR are novel inflammatory markers in BD and are associated with disease activity.

  • CAR and NAR are feasible and inexpensive tools for predicting BD activity.

  • CAR and NAR can predict the critical inflammatory state relevant to the pathological process in BD.

Authors’ contributions

All authors have contributed to designing the study, collecting and analyzing, interpretation of data, and preparing and revising the manuscript. Design of the study: DK, RZ, MH and WM. Recruitment of patients: DK, RZ, MH and WM. Data collection: DK, RZ, MH and WM. Manuscript preparation and revision: DK, RZ, MH and WM. All co-authors have approved the final version.

Each author made significant individual contributions to the following: the conception and design of the study, acquisition of data, analysis and interpretation of data, drafting of the article, critical revisions for important intellectual content, and approval of the final manuscript. Each author believes that the manuscript represents honest work. All authors contributed actively to the study.

Ethical statement

Informed consents were obtained from all patients. An approval was obtained from the ethics committee of Faculty of Medicine, Zagazig University, and the approval number was ZU-IRB 6614/19-9-2019 and the study was conducted in conformity with Declaration of Helsinki.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of interest

There is no conflict of interest to the author's knowledge.

Acknowledgement

None declared.

References
[1]
M.J. Zeidan, D. Saadoun, M. Garrido, D. Klatzmann, A. Six, P. Cacoub.
Behçet's disease physiopathology: a contemporary review.
Auto Immun Highlights, 7 (2016), pp. 4
[2]
H. Yazici, E. Seyahi, G. Hatemi, Y. Yazici.
Behçet syndrome: a contemporary view.
Nat Rev Rheumatol, 14 (2018), pp. 107-119
[3]
M. Pineton de Chambrun, B. Wechsler, G. Geri, P. Cacoub, D. Saadoun.
New insights into the pathogenesis of Behçet's disease.
Autoimmun Rev, 11 (2012), pp. 687-698
[4]
Z. Zhang, Q. Su, L. Zhang, Z. Yang, Y. Qiu, W. Mo.
Diagnostic value of hemoglobin and neutrophil-to-lymphocyte ratio in Behcet Disease.
Medicine (Baltimore), 98 (2019), pp. e18443
[5]
A. Balkarli, A. Kucuk, H. Babur, F. Erbasan.
Neutrophil/lymphocyte ratio and mean platelet volume in Behçet's disease.
Eur Rev Med Pharmacol Sci, 20 (2016), pp. 3045-3050
[6]
A. Avci, D. Avci.
Serum prolactin levels in Behçet's disease. Is there a relationship between Behcet's disease and prolactin as in other autoimmune diseases?.
Acta Dermatovenerol Croat, 21 (2013), pp. 52-53
[7]
M. Ygündüz, N. Bavbek, M. Öztürk, O. Kaftan, A. Kosar, S. Kirazli.
Serum beta 2-microglobulin reflects disease activity in Behçet's disease.
Rheumatol Int, 22 (2002), pp. 5-8
[8]
M. Calis, F. Ates, C. Yazici, K. Kose, M. Kirnap, M. Demir, et al.
Adenosine deaminase enzyme levels, their relation with disease activity, and the effect of colchicine on adenosine deaminase levels in patients with Behçet's disease.
Rheumatol Int, 25 (2005), pp. 452-456
[9]
A.Y. Gasparyan, L. Ayvazyan, U. Mukanova, M. Yessirkepov, G.D. Kitas.
The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases.
Ann Lab Med, 39 (2019), pp. 345-357
[10]
N. Afifi, M. Medhat, B. Abdel Ghani, A.M. Mohamed Ali Hassan, H.G.E. Behiry.
Value of albumin-fibrinogen ratio and CRP-albumin ratio as predictor marker of disease activity in Egyptian RA patients, correlated with musculoskeletal sonography.
Open Access Rheumatol, 12 (2020), pp. 241-248
[11]
İ. Sunar, Ş. Ataman.
Serum C-reactive protein/albumin ratio in rheumatoid arthritis and its relationship with disease activity, physical function, and quality of life.
Arch Rheumatol, 35 (2020), pp. 247-253
[12]
T. Tsujino, K. Komura, T. Hashimoto, R. Muraoka, N. Satake, T. Matsunaga, et al.
C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma – a data from multi-institutional study in Japan.
[13]
E. Bozkurt, E. Muhafiz, D. Sengul, T. Uçak, M. Atum.
Can the CRP/albumin ratio be used as a new indicator of activation in patients with uveitis?.
Ocul Immunol Inflamm, 3 (2020), pp. 1-6
[14]
S. Kayabasi, O. Hizli, S. Cayir.
A novel predictor parameter for active recurrent aphthous stomatitis: C-reactive protein to albumin ratio.
Cureus, 11 (2019), pp. e5965
[15]
O.T. Ranzani, F.G. Zampieri, D.N. Forte, L.C. Azevedo, M. Park.
C-reactive protein/albumin ratio predicts 90-day mortality of septic patients.
[16]
N. Li, G.W. Tian, Y. Wang, H. Zhang, Z.H. Wang, G. Li.
Prognostic role of the pretreatment c-reactive protein/albumin ratio in solid cancers: a meta-analysis.
Sci Rep, 7 (2017), pp. 41298
[17]
Y. Gong, D. Li, B. Cheng, B. Ying, B. Wang.
Increased neutrophil percentage-to-albumin ratio is associated with all-cause mortality in patients with severe sepsis or septic shock.
Epidemiol Infect, 148 (2020), pp. e87
[18]
G.S. Selders, A.E. Fetz, M.Z. Radic, G.L. Bowlin.
An overview of the role of neutrophils in innate immunity, inflammation and host-biomaterial integration.
Regen Biomater, 4 (2017), pp. 55-68
[19]
N. Ataş, H. Babaoğlu, E. Demirel, B. Çelik, R. Bilici Salman, H. Satış, et al.
Use of prognostic nutritional index in the evaluation of disease activity in patients with Behçet's disease.
Eur J Rheumatol, 7 (2020), pp. 99-104
[20]
F. Davatchi, S. Assaad-Khalil, K.T. Calamia, J.E. Crook, B. Sadeghi-Abdollahi, M. Schirmer.
The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria.
J Eur Acad Dermatol Venereol, 28 (2014), pp. 338-347
[21]
F.S. Neves, J.C. Moraes, S.C. Kowalski, C. Goldenstein-Schainberg, L.V. Lage, C.R. Gonçalves.
Cross-cultural adaptation of the Behçet's Disease Current Activity Form (BDCAF) to Brazilian Portuguese language.
Clin Rheumatol, 26 (2007), pp. 1263-1267
[22]
N. Seringec Akkececi, G. Yildirim Cetin, H. Gogebakan, C. Acipayam.
The C-reactive protein/albumin ratio and complete blood count parameters as indicators of disease activity in patients with Takayasu arteritis.
Med Sci Monit, 5 (2019), pp. 1401-1409
[23]
M. Melikoglu, Z. Topkarci.
Is there a relation between clinical disease activity and acute phase response in Behcet's disease?.
Int J Dermatol, 53 (2014), pp. 250-254
[24]
Y.H. Balcioglu, S.S. Kirlioglu.
C-reactive protein/albumin and neutrophil/albumin ratios as novel inflammatory markers in patients with schizophrenia.
Psychiatry Investig, 17 (2020), pp. 902-910
[25]
M. Hammad, O.Z. Shehata, S.M. Abdel-Latif, A.M.M. El-Din.
Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in Behçet's disease: which and when to use?.
Clin Rheumatol, 37 (2018), pp. 2811-2817
[26]
S. Shadmanfar, M. Masoumi, F. Davatchi, et al.
Correlation of clinical signs and symptoms of Behçet's disease with platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR).
Immunol Res, 69 (2021), pp. 363-371
[27]
G. Qin, J. Tu, L. Liu, L. Luo, J. Wu, L. Tao, et al.
Serum albumin and C-reactive protein/albumin ratio are useful biomarkers of Crohn's disease activity.
Med Sci Monit, 22 (2016), pp. 4393-4400
[28]
M. Kim, Y.G. Park, Y.H. Park.
C-reactive protein/albumin ratio as an indicator of disease activity in Behçet's disease and human leukocyte antigen-B27-associated uveitis.
Graefes Arch Clin Exp Ophthalmol, (2021),
[29]
S. Sarhan, N. Sherby, S. Alian, N. Raafat, Y. El-meligui.
Association between C reactive protein/albumin ratio and systemic sclerosis disease activity.
Int J Pharm Res, 13 (2021), pp. 3
[30]
G. Costagliola, S. Cappelli, R. Consolini.
Behçet's disease in children: diagnostic and management challenges.
Therap Clin Risk Manag, 16 (2020), pp. 495-507
Copyright © 2022. Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología
Download PDF
Idiomas
Reumatología Clínica (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?